Systemic 100% oxygen delivered at supra-atmospheric pressure — hyperoxygenation, neovascularization, and fibroblast stimulation for refractory chronic wounds
Hyperbaric oxygen therapy (HBOT) is a resource-intensive adjunctive therapy, and appropriate patient selection is the single greatest determinant of cost-effective, clinically meaningful outcomes. The Undersea and Hyperbaric Medical Society (UHMS) maintains an approved indications list; among chronic wound conditions, the strongest evidence supports diabetic foot ulcers (Wagner grade ≥3), compromised grafts/flaps, chronic refractory osteomyelitis, and delayed radiation tissue injury (osteoradionecrosis, soft tissue radionecrosis).
Comprehensive pre-treatment screening for chronic wound HBOT candidacy:
1. Clinical indication confirmation: • Diabetic foot ulcer: Wagner grade 3 or higher (deep ulcer with abscess/osteomyelitis) that has failed ≥30 days of standard wound care (debridement, offloading, infection control, revascularization if indicated) • Chronic refractory osteomyelitis: failed conventional surgical debridement + culture-directed antibiotics • Compromised surgical flap/graft: evidence of marginal perfusion/early necrosis threatening flap viability • Delayed radiation injury: osteoradionecrosis of the mandible, radiation cystitis, radiation proctitis, soft tissue radionecrosis — typically presenting months to years after radiotherapy • Necrotizing soft tissue infection (gas gangrene) and crush injury with compartment syndrome — urgent/emergent indications, not chronic wound pathway but relevant differential
2. Pre-treatment screening battery: • Chest X-ray: mandatory to exclude undiagnosed bullous lung disease/pneumothorax — a treated pneumothorax can convert to a tension pneumothorax under hyperbaric pressure during decompression, a life-threatening emergency • Otologic exam: assess for eustachian tube dysfunction; patients unable to equalize middle ear pressure need myringotomy tubes before starting a course, or will suffer barotrauma every session • Vascular assessment: ABI/toe pressures to confirm adequate arterial inflow — HBOT is an adjunct to, not a substitute for, surgical revascularization when a correctable arterial lesion exists • Baseline transcutaneous oximetry (TcPO2): measured on room air, then repeated breathing 100% O2 at 2.0–2.4 ATA in-chamber ("oxygen challenge test") — an in-chamber TcPO2 rising above 200 mmHg strongly predicts a favorable healing response; failure to rise above ~100 mmHg predicts poor response and should prompt reconsideration • Blood glucose optimization: hyperbaric oxygen transiently lowers blood glucose — diabetic patients require glucose monitoring before/after each session, particularly those on insulin • Medication review: bleomycin (risk of pulmonary toxicity at hyperbaric pressure — absolute contraindication for concurrent use), doxorubicin, cisplatin (relative caution), disulfiram (blocks superoxide dismutase, theoretical oxygen toxicity risk)
3. Absolute and relative contraindications: • Absolute: untreated pneumothorax • Relative: severe COPD with CO2 retention/bullae, uncontrolled seizure disorder, high fever (increases oxygen toxicity seizure risk), pregnancy (relative — case-by-case), concurrent bleomycin therapy, claustrophobia (may require multiplace chamber or anxiolytic pre-medication)
4. Expected course length and reimbursement considerations: • Standard DFU course: 20–40 sessions; many payers (including U.S. Medicare) require formal documentation of failed standard care and periodic reassessment to continue authorization • Cost: approximately $300–$1000+ per session depending on setting — cost-effectiveness analyses support HBOT primarily in Wagner grade 3+ DFU where it demonstrably reduces major amputation risk
Each HBOT session begins with a controlled compression phase, during which chamber pressure is gradually increased from ambient (1.0 ATA) to the prescribed treatment pressure — typically 2.0 to 2.5 ATA for chronic wound protocols. The rate of compression is carefully controlled to allow the patient to equalize pressure in the middle ear, sinuses, and any other gas-containing body space, preventing barotrauma, the most common adverse event associated with HBOT.
Understanding the mechanics of hyperbaric compression is essential to both delivering safe treatment and appreciating why HBOT sessions are structured the way they are:
1. Chamber types: • Monoplace chamber: acrylic cylinder accommodating one patient, pressurized directly with 100% oxygen (patient breathes ambient chamber gas — pure O2). Lower cost, easier to site, but limits access for staff during treatment (communication via intercom/observation) and requires strict fire-safety protocols given the pure O2 atmosphere • Multiplace chamber: larger steel chamber accommodating multiple patients (and sometimes an attendant), pressurized with compressed air; patients breathe 100% O2 via tight-fitting mask, head tent, or endotracheal tube if intubated. Allows direct staff access for critically ill patients, more complex equipment/higher cost
2. Compression phase physiology (Boyle's Law: P1V1 = P2V2): • As ambient pressure rises, gas volume in any enclosed body space (middle ear, sinuses, dental caries with trapped air, bowel gas) compresses proportionally • Middle ear: the eustachian tube must actively open (via swallowing, jaw movement, or Valsalva maneuver) to equalize pressure between the middle ear and the pressurized chamber environment; failure to equalize causes pain, hemotympanum, or tympanic membrane rupture in severe cases • Patients are taught equalization techniques before the first session and coached continuously during compression by chamber staff/intercom • Patients with chronic eustachian tube dysfunction (common in the diabetic/elderly population typical of chronic wound HBOT candidates) may require prophylactic bilateral myringotomy with tube placement before starting a course
3. Compression rate: • Typically 1 ATA increase over 5–10 minutes, individualized — faster compression increases barotrauma risk, especially in patients who need more time to equalize • Patient can request a "hold" or slower compression at any point if unable to equalize
4. Reaching treatment depth: • Once target pressure (usually 2.0–2.5 ATA, equivalent to 33–49 feet of seawater depth) is reached, the treatment ("bottom time") phase begins • Total session time: typically 90–120 minutes of treatment pressure time, often structured as periods of 100% O2 breathing interspersed with brief "air breaks" (5 minutes of ambient air breathing every 20–30 minutes) to reduce oxygen toxicity risk while preserving therapeutic benefit
5. Decompression: • Mirror-image gradual pressure reduction back to 1.0 ATA at the end of the session, again allowing gas spaces to re-equalize outward • Rapid or uncontrolled decompression risk: reverse ear block, and in patients with undiagnosed pulmonary bullae, risk of pneumothorax/arterial gas embolism — underscoring the importance of pre-treatment chest imaging
The central physiological mechanism of HBOT is dramatically increasing the amount of oxygen physically dissolved in blood plasma — independent of hemoglobin saturation, which is already near 100% on room air in most patients. At 2.4 ATA breathing 100% oxygen, plasma-dissolved oxygen rises roughly twenty-fold, from approximately 0.3 mL O2/dL blood at sea level to approximately 6 mL O2/dL — a quantity sufficient to meet resting tissue metabolic oxygen demand through plasma alone, bypassing the need for red blood cell delivery into poorly perfused, hypoxic wound tissue.
The physics and physiology underlying hyperoxygenation explain why HBOT specifically benefits hypoxic, poorly-perfused chronic wounds:
1. Henry's Law and dissolved oxygen: • The amount of gas dissolved in a liquid is directly proportional to the partial pressure of that gas above the liquid • At sea level (1.0 ATA), breathing room air (21% O2), arterial pO2 ≈ 95–100 mmHg, and dissolved plasma O2 ≈ 0.3 mL/dL • At 2.4 ATA breathing 100% oxygen, inspired pO2 rises to roughly 1800 mmHg, and arterial pO2 reaches 1200–1500 mmHg — dissolved plasma O2 rises to approximately 6 mL/dL • Normal resting tissue oxygen consumption is approximately 6 mL O2/dL blood — meaning at treatment pressure, plasma alone can theoretically sustain resting tissue metabolism without any contribution from hemoglobin-bound oxygen
2. Why this matters specifically for wound hypoxia: • Chronic wounds are characterized by microvascular damage, capillary dropout, edema-increased diffusion distance, and in diabetic/vasculopathic patients, macrovascular arterial insufficiency • Hemoglobin-bound oxygen delivery depends on red blood cells physically traversing capillaries — in a wound bed with capillary damage or occlusion, red cells (7-8 micron diameter) may be unable to pass through the narrowed, damaged microvasculature • Plasma, being a fluid without cellular size constraints, can perfuse through far more compromised microvascular channels than red blood cells, delivering oxygen to tissue that would otherwise remain hypoxic despite adequate hemoglobin saturation • The result: HBOT transiently raises wound tissue pO2 from typically <20–30 mmHg (chronic hypoxic wound) to 200–400+ mmHg during treatment — a level associated with restoration of neutrophil oxidative killing capacity, fibroblast collagen synthesis, and angiogenic signaling
3. Duration of effect and rationale for repeated daily sessions: • The hyperoxygenation effect itself is transient — tissue pO2 returns toward baseline within hours after leaving the chamber • However, repeated daily exposure over a full treatment course produces durable downstream biological effects (angiogenesis, collagen synthesis, leukocyte function) that persist and accumulate — this is why a full course of 20-40 sessions, not a single treatment, is required for clinical benefit • Analogy: each session is a "priming pulse" that triggers hours-to-days of downstream cellular signaling (HIF-1α/VEGF upregulation, fibroblast activation) — the therapeutic benefit is cumulative across the treatment course, not simply the acute oxygenation during the 90–120 minute session itself
4. Antimicrobial and immune effects: • Neutrophil oxidative bacterial killing (via NADPH oxidase-generated reactive oxygen species) is oxygen-tension dependent and severely impaired below tissue pO2 of ~30 mmHg — common in chronic wounds and a major contributor to infection susceptibility • Restoring tissue pO2 during HBOT sessions transiently restores neutrophil killing capacity, contributing to infection control in refractory osteomyelitis and necrotizing infections • Direct bacteriostatic/bactericidal effect on obligate anaerobes (e.g., Clostridium perfringens in gas gangrene) at high pO2
Beyond the acute hyperoxygenation of each session, the therapeutic power of HBOT for chronic wounds comes from cumulative biological adaptations triggered by repeated hyperoxic/relative-hypoxic cycling: angiogenesis (new capillary formation) and collagen synthesis by fibroblasts, both of which are fundamentally oxygen-tension-dependent processes. This is why clinical benefit accrues gradually over a multi-week course rather than after a single or few treatments.
The molecular mechanisms by which repeated HBOT sessions drive durable tissue repair are increasingly well characterized:
1. Hyperoxic-hypoxic cycling and angiogenesis: • Counterintuitively, angiogenic signaling in HBOT is driven not simply by high oxygen, but by the oscillation between hyperoxia (during treatment) and relative hypoxia (upon returning to room air between/after sessions) • This cycling upregulates hypoxia-inducible factor 1-alpha (HIF-1α) and downstream vascular endothelial growth factor (VEGF) expression in wound tissue, along with stromal-cell derived factor-1 (SDF-1), which recruits circulating bone-marrow-derived endothelial progenitor cells to the wound • Reactive oxygen species (ROS) generated during hyperoxic exposure, at controlled therapeutic levels, act as signaling molecules (not merely damaging agents) that activate growth factor transcription — a hormetic, dose-dependent effect central to HBOT's mechanism • Net effect over a full course: measurable increase in capillary density and blood flow within previously hypovascular tissue — this is the physiological basis for HBOT's efficacy in radiation-damaged tissue, which is characteristically hypovascular, hypocellular, and hypoxic ("the 3 H's" of radiation injury, per Marx)
2. Fibroblast collagen synthesis is oxygen-dependent biochemistry: • Collagen synthesis requires post-translational hydroxylation of proline and lysine residues by the enzymes prolyl hydroxylase and lysyl hydroxylase • These enzymes use molecular oxygen as a direct co-substrate (not merely a permissive cofactor) — without adequate oxygen, hydroxylation fails, unstable collagen triple helices cannot form, and the collagen is degraded intracellularly rather than secreted • Tissue pO2 below approximately 30 mmHg significantly impairs this hydroxylation reaction — a threshold commonly undershot in chronic hypoxic wounds even at baseline • By transiently elevating tissue pO2 to 200-400+ mmHg during each session, HBOT provides a sufficient oxygen substrate window for fibroblasts to synthesize and secrete properly hydroxylated, stable collagen — contributing to wound bed granulation and tensile strength over the treatment course
3. Marx's classic irradiated tissue model (Marx RE, 1990s foundational HBOT research): • Robert Marx's studies on osteoradionecrosis established the "3 H" pathophysiology of radiation injury: Hypoxic, Hypovascular, Hypocellular tissue • Demonstrated histologically that a course of HBOT (typically 20-30 sessions preoperatively for surgical cases) measurably increases capillary density and fibroblast cellularity in previously irradiated tissue, improving surgical outcomes (e.g., dental extraction, mandibular reconstruction) in a field that would otherwise have unacceptably high wound breakdown/osteoradionecrosis risk • This work forms the evidentiary basis for the "20/10" protocol still used in some centers: 20 preoperative HBOT sessions, surgery, then 10 postoperative sessions, for elective procedures in previously irradiated tissue beds
4. Why the effect is cumulative and dose-dependent: • A single session's angiogenic/collagen-synthesis stimulus is modest; clinically meaningful new capillary networks and mature collagen deposition require repeated stimulation across dozens of sessions • This underlies the standard 20–40 session course length and the recommendation to reassess (not abandon) therapy at intervals of 10-15 sessions before declaring treatment failure
The two-part mechanism — acute plasma hyperoxygenation correcting immediate tissue hypoxia during each session, and cumulative HIF-1α/VEGF-driven angiogenesis plus oxygen-dependent collagen hydroxylation building durable new vasculature and matrix over the full course — explains why HBOT candidacy assessment (Stage 1) and course completion adherence (Stage 5) are just as clinically important as the oxygen delivery itself.
A standard HBOT course for a chronic wound indication runs 20 to 40 daily sessions (typically 5 days/week, 90–120 minutes at treatment pressure), with formal reassessment of wound measurements and TcPO2 at defined intervals — most commonly every 10 to 15 sessions. Objective evidence of a positive trajectory is required to justify continuing; the absence of measurable improvement by session 15–20 defines a "non-responder" and should prompt discontinuation and reconsideration of the treatment plan, consistent with UHMS practice guidance and most payer authorization frameworks.
Completing a full HBOT course requires structured monitoring for both efficacy and treatment-related adverse effects:
1. Evidence for diabetic foot ulcer outcomes: • Cochrane systematic reviews and multiple RCTs support HBOT as an adjunct (not a substitute for standard care) in Wagner grade 3+ DFU, showing improved short-term wound healing rates and reduced major amputation risk • Effect size varies across studies (heterogeneous populations, protocols); pragmatic clinical benefit is most consistently demonstrated in patients with the "oxygen challenge test" predictive response described in Stage 1 (in-chamber TcPO2 rising above ~200 mmHg) • HBOT does not replace revascularization — in patients with a correctable arterial lesion, vascular intervention should precede or accompany HBOT, not substitute for it
2. Evidence for osteoradionecrosis and radiation tissue injury: • Strongest and most consistent HBOT evidence base among chronic wound indications, particularly the Marx protocol for pre/post-surgical management of irradiated mandibular tissue • RCT evidence (e.g., Cochrane review, ORN04 trial) supports HBOT for established mandibular osteoradionecrosis refractory to conservative management
3. Session-by-session monitoring during the course: • Wound measurement (length × width, tracing or digital planimetry) at baseline and every 10-15 sessions — percent area reduction trajectory is the primary efficacy metric • TcPO2 reassessment: rising room-air TcPO2 over the course (e.g., from <40 mmHg baseline toward >50 mmHg reflects durable improvement in tissue perfusion, not just the transient in-chamber effect • Photographic documentation at each reassessment interval for objective comparison
4. Adverse effects requiring monitoring across a multi-week daily course: • Reversible myopia: common with courses beyond 20 sessions, related to lens changes from prolonged hyperoxia; typically resolves within weeks of course completion — patients should be counseled preemptively • Oxygen toxicity seizure (CNS): rare (~1 in 10,000 to 1 in 50,000 treatments) but the most feared acute adverse event; mitigated by air breaks during each session and staying within established pressure/time limits; fully reversible on decompression with no lasting sequelae in the large majority of cases • Pulmonary oxygen toxicity: cumulative, dose-related; monitored using cumulative pulmonary toxicity dose tracking in patients on very long courses • Barotrauma (ear/sinus): most common adverse event overall, mitigated by equalization training and controlled compression rates (Stage 2) • Confinement anxiety/claustrophobia: addressed with pre-treatment counseling, multiplace chamber option, or anxiolytic premedication when needed • Relative hypoglycemia in diabetic patients: blood glucose should be checked before and after sessions, particularly in insulin-treated patients
5. Course completion and transition to maintenance wound care: • On completing the prescribed course with objective response, patients transition back to standard wound care (debridement, offloading, moisture management per the TIME framework) to consolidate gains • HBOT is not typically continued indefinitely — it is a time-limited adjunct intended to overcome a specific hypoxia-driven healing plateau, not a permanent component of chronic wound management
The most consequential clinical decision point in an HBOT course is the session 15–20 reassessment: continuing an unresponsive course wastes significant healthcare resources and delays consideration of alternative strategies (revascularization, amputation-level decision-making, palliative approach), while premature discontinuation of a genuinely responding course forfeits the cumulative angiogenic benefit that builds specifically over the second half of a full 20–40 session protocol.